Table 2.

Recommendations related to pregnancy in hypertension guidelines.

Aspects/recommendations	WHO 2021 [9]	ISH 2020 [10]	ESC/ESH 2018 [2]	ACC/AHA 2017 [3]a	Latin American 2016 [11]	NICE 2019 [https://www.nice.org.uk/guidance/ng133]b	Australian 2016 [29]c	Japanese 2019 [34]	Chinese 2018 [33]	Korean 2018 [30–32]
Definition of hypertension in pregnancy (mmHg)	≥140/90	≥140/90	≥140/90	≥140/90	≥140/90	≥140/90	≥140/90	≥140/90	NR	≥140/90
Classification of hypertensive disorders in pregnancy	√	√	√	√	NR	√	√	√	√	√
Aspirin to prevent preeclampsia in high-risk pregnancy	NR	Yes, 75–162 mg 12th week	Yes, 100–150 mg 12th week	Yes, 60–80 mg late 1st trimester	Yes, 100 mg, before 6th week	Yes, 75–150 mg 12th week	Yes, low dose	NR	Yes, low dose, 12th week	NR
Treatment of severe hypertension	√	√	√	√	√	√	√	√	√	√
Treatment of non-severe hypertension	If comorbidities	√	√	No	No	√	Individualize	No	√	√
On-treatment BP target of severe hypertension (mmHg)	NR	NR	NR	140–150/90–99	NR	130–150/80–100	NR	<160/110	NR	<150/100 Not <80
BP threshold to initiate drug treatment in non-severe hypertension (mmHg)	≥160/105 Diastolic >90 (if comorbidities)	>150/95	>150/95 or >140/90 if comorbidities	<160/110 only if comorbidities	≥160/110	≥140/90	≥140/90	NR	≥150/100	>150/95
On-treatment BP target of mild hypertension (mmHg)	NR	NR	<140/90	NR	NR	<135/85 Not <110/70	NR	NR	<150/100 Not <130/80	<150/100 Not <80
Preferred agent(s) to treat severe hypertension	NR	iv labetalol iv esmolol iv urapidiliv nicardipine	iv labetalol po nifedipine	iv hydralazine po nifedipine	NR	iv labetalol po nifedipine iv hydralazine	iv labetalol po nifedipine iv hydralazine	iv nicardipine iv nitroglycerin iv hydralazine	NR	iv labetalol
Preferred agents to treat non-severe hypertension	po labetalol po nifedipine po verapamil po methyldopa po hydralazine	po labetalol po nifedipine po nicardipine po methyldopa	po labetalol po calcium channel blockers	po labetalol	po labetalol po methyldopa po nifedipine po amlodipine	po labetalol po methyldopa po nifedipine po enalaprilb	po labetalol po methyldopa po nifedipine po oxprenolol	po labetalol po methyldopa po nifedipined po hydralazinee	po labetalol po methyldopa po nifedipine	po labetalol po methyldopa po nifedipine

BP blood pressure, NR not reported.

^a2013 American College of Obstetricians and Gynecologists’ guideline.

^bTo treat hypertension during puerperium.

^c2014 Society of Obstetric Medicine of Australian and New Zealand (SOMANZ) guideline.

^dAfter the 20th week.

^eAs an alternative agent in gestational hypertension.